Elite Pharma reports Q2 FY27 revenue increase
Elite Pharmaceuticals reported Q2 FY27 revenue of $40.1M, up 10.4%, citing increased sales from its Elite label amphetamine and naltrexone product lines; the company will host a conference call on November 13, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed